|
|
|
|
|
|
|
 Serc® (Betaserc®, Vasomotal® betahistine dihydrochloride) is the world leader in the treatment of Ménière’s disease and vestibular vertigo. Serc® is available in over 90 countries worldwide and over 130 million patients have been treated with Serc®.
Ménière’s disease affects the inner ear fluid pressure and is characterized by fluctuating hearing loss, tinnitus (sound without external cause), and rotational vertigo (sense that the world is spinning around you). In addition to improving vertigo, tinnitus and deafness Serc® results in a steady decrease in the intensity and frequency of vertigo attacks, that often totally incapacitate sufferers.
Serc® 24 mg twice daily is the recommended effective dose. It is effective but non-sedating, so patients can remain alert and maintain their active lifestyles.
Additionally, Serc® does not interfere with the natural adaptation of the brain to the new situation of vertigo. This process is called 'vestibular compensation', and it is the body's natural response to vertigo. To hasten compensation an active lifestyle is very important. Unlike more sedative treatments, Serc® does not interfere with this compensation process.
Solvay Pharmaceuticals makes considerable contributions to fundamental vertigo research and is committed to improving the quality of life of vertigo patients. |
|
|
|
|
|
